Palatin Technologies Financials
PTN Stock | USD 1.08 0.07 6.09% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 0.96 | 1.0116 |
|
|
The essential information of the day-to-day investment outlook for Palatin Technologies includes many different criteria found on its balance sheet. An individual investor should monitor Palatin Technologies' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Palatin Technologies.
Cash And Equivalents |
|
Palatin | Select Account or Indicator |
Palatin Technologies Stock Summary
Palatin Technologies competes with Candel Therapeutics, Unicycive Therapeutics, Cardio Diagnostics, Virax Biolabs, and Senti Biosciences. Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company was founded in 1986 and is based in Cranbury, New Jersey. Palatin Technologies operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 33 people.Foreign Associate | Germany |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NYSE MKT Exchange |
ISIN | US6960774031 |
CUSIP | 696077403 696077502 696077304 |
Location | New Jersey; U.S.A |
Business Address | Cedar Brook Corporate |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | palatin.com |
Phone | 609 495 2200 |
Currency | USD - US Dollar |
Palatin Technologies Key Financial Ratios
Return On Equity | -6.23 | ||||
Operating Margin | (23.79) % | ||||
Price To Sales | 5.01 X | ||||
Revenue | 4.49 M | ||||
Gross Profit | (18.2 M) |
Palatin Technologies Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 85.1M | 67.3M | 36.1M | 17.9M | 10.7M | 10.2M | |
Other Current Liab | 2.9M | 9.2M | 12.2M | 9.9M | 4.7M | 4.9M | |
Net Debt | (81.6M) | (58.9M) | (28.8M) | (6.9M) | (8.9M) | (9.4M) | |
Retained Earnings | (318.2M) | (351.8M) | (388.0M) | (415.5M) | (441.8M) | (419.7M) | |
Accounts Payable | 715.7K | 640.7K | 3.2M | 4.3M | 4.1M | 4.3M | |
Cash | 82.9M | 60.1M | 29.9M | 8.0M | 9.5M | 9.1M | |
Other Current Assets | 609.9K | 3.1M | 1.9M | 1.9M | 242.3K | 230.2K | |
Total Liab | 4.9M | 17.6M | 19.8M | 17.8M | 10.9M | 12.8M | |
Total Current Assets | 83.6M | 65.9M | 34.6M | 16.3M | 9.8M | 9.3M | |
Short Term Debt | 312.8K | 703.7K | 944.1K | 920.9K | 853.1K | 1.2M | |
Common Stock | 2.3M | 2.3M | 92.7K | 116.6K | 179.3K | 170.3K | |
Net Tangible Assets | 80.2M | 49.7M | 16.3M | 134.0K | 154.1K | 146.4K | |
Capital Surpluse | 396.1M | 399.1M | 404.2M | 415.6M | 477.9M | 380.5M |
Palatin Technologies Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 20.1K | 23.4K | 29.7K | 20.0K | 17.1K | 16.3K | |
Total Revenue | 118.0K | (188.6K) | 1.5M | 4.9M | 4.5M | 4.3M | |
Gross Profit | 118.0K | (336.4K) | 1.3M | 4.4M | 4.4M | 4.2M | |
Operating Income | (23.6M) | (33.4M) | (36.6M) | (32.5M) | (22.5M) | (23.6M) | |
Ebit | (23.6M) | (33.8M) | (36.6M) | (32.5M) | (29.4M) | (27.9M) | |
Research Development | 14.0M | 12.9M | 21.3M | 22.6M | 22.4M | 20.5M | |
Ebitda | (23.5M) | (33.4M) | (36.5M) | (32.2M) | (29.0M) | (27.6M) | |
Income Before Tax | (22.4M) | (33.6M) | (36.2M) | (32.2M) | (29.7M) | (28.2M) | |
Net Income | (22.4M) | (33.6M) | (35.8M) | (27.5M) | (29.7M) | (28.2M) | |
Income Tax Expense | (44.1K) | (27.7K) | (390.1K) | (4.7M) | (7.8M) | (7.4M) | |
Cost Of Revenue | 14.0M | 147.8K | 217.5K | 418.5K | 97.6K | 92.8K | |
Interest Income | 1.2M | 212.4K | 390.2K | 242K | 217.8K | 206.9K | |
Net Interest Income | (20.1K) | (23.4K) | (29.7K) | (20.0K) | (17.1K) | (18.0K) |
Palatin Technologies Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 39.3M | (22.7M) | (30.2M) | (21.9M) | 1.5M | 1.6M | |
Free Cash Flow | 41.3M | (22.7M) | (30.2M) | (28.9M) | (31.5M) | (29.9M) | |
Depreciation | 64.2K | 51.1K | 126.7K | 288.3K | 339.1K | 503.1K | |
Other Non Cash Items | 299.0K | 19.4M | 203.9K | (2.6M) | (530.3K) | (556.8K) | |
Capital Expenditures | 62.9K | 5.7K | 261.4K | 433.9K | 42.5K | 40.4K | |
Net Income | (22.4M) | (33.6M) | (36.2M) | (27.5M) | (29.7M) | (28.2M) | |
End Period Cash Flow | 82.9M | 60.1M | 29.9M | 8.0M | 9.5M | 9.1M | |
Change To Inventory | (524.6K) | (987.2K) | 217.5K | 418.5K | (1.2M) | (1.1M) | |
Net Borrowings | (6.5M) | (832.9K) | (56.5K) | (100.9K) | (90.8K) | (95.4K) | |
Dividends Paid | 115.8K | 2.5M | 221.3K | 146.1K | 168.0K | 303.1K | |
Change To Netincome | 3.1M | 22.8M | 2.7M | 1.2M | 1.4M | 1.3M | |
Investments | (62.9K) | (5.7K) | (261.4K) | (3.4M) | 12.5M | 13.1M |
Palatin Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Palatin Technologies's current stock value. Our valuation model uses many indicators to compare Palatin Technologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Palatin Technologies competition to find correlations between indicators driving Palatin Technologies's intrinsic value. More Info.Palatin Technologies is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Palatin Technologies' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Palatin Technologies' earnings, one of the primary drivers of an investment's value.Palatin Technologies Systematic Risk
Palatin Technologies' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Palatin Technologies volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Palatin Technologies correlated with the market. If Beta is less than 0 Palatin Technologies generally moves in the opposite direction as compared to the market. If Palatin Technologies Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Palatin Technologies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Palatin Technologies is generally in the same direction as the market. If Beta > 1 Palatin Technologies moves generally in the same direction as, but more than the movement of the benchmark.
Palatin Technologies Thematic Clasifications
Palatin Technologies is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
Biotech | View |
Today, most investors in Palatin Technologies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Palatin Technologies' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Palatin Technologies growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Palatin Technologies December 4, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Palatin Technologies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Palatin Technologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Palatin Technologies based on widely used predictive technical indicators. In general, we focus on analyzing Palatin Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Palatin Technologies's daily price indicators and compare them against related drivers.
Information Ratio | (0.10) | |||
Maximum Drawdown | 25.15 | |||
Value At Risk | (10.08) | |||
Potential Upside | 9.57 |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Palatin Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Palatin Stock, please use our How to Invest in Palatin Technologies guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palatin Technologies. If investors know Palatin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palatin Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.98) | Revenue Per Share 0.306 | Quarterly Revenue Growth (0.80) | Return On Assets (1.32) | Return On Equity (6.23) |
The market value of Palatin Technologies is measured differently than its book value, which is the value of Palatin that is recorded on the company's balance sheet. Investors also form their own opinion of Palatin Technologies' value that differs from its market value or its book value, called intrinsic value, which is Palatin Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palatin Technologies' market value can be influenced by many factors that don't directly affect Palatin Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palatin Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Palatin Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palatin Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.